Atlas Trials

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment

Clinical trial NCT06663787 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06663787
Sponsor
Nagoya City University
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Breast Cancer, MetastaticHER2 + Breast Cancer
Start date
2024-04-01
Primary completion
2026-12-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.